Get in touch

Write to us if you think the analysis is wrong or have data that would test it, want to build on these ideas, or are asking the same questions.

We also advise biopharma companies and investors on valuation, and we're building software tools for biotech investing. If either could help with what you're working on, tell us about it.

• Research. Corrections, counter-evidence and data are all welcome.
• Advisory. Valuation work for companies and investors.
• Tools. Software for biotech investing, in development.